Skip to main content

Primary Sclerosing Cholangitis clinical trials at UCSF

3 in progress, 2 open to eligible people

Primary sclerosing cholangitis is a liver disease that causes inflammation and scarring in the bile ducts. UCSF is conducting clinical trials to find new treatments for this disease. One trial is looking at risk factors and prediction models for liver decompensation, and another is testing the safety and effectiveness of a drug called PLN-74809 for people with PSC.

Showing trials for
  • Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

    open to eligible people ages 18-75

    A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis

    San Francisco, California and other locations

  • Liver Cirrhosis Network Cohort Study

    open to eligible people ages 18 years and up

    Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

    San Francisco, California and other locations

  • Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

    Sorry, not yet accepting patients

    This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

    San Francisco, California and other locations

Last updated: